This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoGenomics Launches NeoTYPE™ Prognostic Panel For Chronic Lymphocytic Leukemia; Includes First U.S. Clinical Molecular Test For SF3B1 Mutations

FT. MYERS, Fla., Aug. 6, 2012 /PRNewswire/ -- NeoGenomics, Inc. (NASD OTC BB: NGNM), a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched the first molecular assay for clinical use in the United States that detects mutations in the SF3B1 gene (splicing factor 3b, subunit 1).  This test is offered as a stand-alone test and in conjunction with a new comprehensive prognostic profiling panel for patients with chronic lymphocytic leukemia (CLL). The CLL Profile panel also includes assays for IgVH mutation analysis, ZAP-70 expression measured by flow cytometry, and FISH tests targeting abnormalities of certain genes associated with CLL.

CLL accounts for about one-third of the 47,000 leukemia cases diagnosed in the U.S. each year.  SF3B1 mutations in CLL have been associated with aggressive disease.  SF3B1 mutation analysis is also important for diagnosing and determining prognosis in patients with myelodysplastic syndrome (MDS).  The NeoTYPE CLL Profile is the company's first hematology profiling test panel.  Five NeoTYPE profiles to characterize breast, gastric, colorectal, lung, and other solid tumors were previously launched in mid-July.

Douglas VanOort, the company's Chairman and CEO, commented, "This offering is part of NeoGenomics commitment to be on the leading edge of cancer genetics testing with a state-of-the-art menu of services.  Our new NeoTYPE Cancer Profile tests are designed to provide physicians with comprehensive information about the biology and potential clinical behavior of specific cancers so patients can be offered the best quality personalized management and therapies that are targeted to their specific cancers."

Dr. Maher Albitar, the Company's Chief Medical Officer and Director of Research and Development, commented, "Chronic lymphocytic leukemia can have significantly different severity depending on the  genomic makeup of the leukemic cells.  Many patients with the disease may go on with their life without needing any therapy, but in some patients the disease may progress rapidly.  Our goal is to provide patients and their treating physicians with the most comprehensive prognostic indicators available so that treatment options and management can be well planned and precisely tailored for each individual patient." 

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics testing, the fastest growing segment of the laboratory industry.  The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, morphology studies, anatomic pathology and molecular genetic testing.  Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL.  NeoGenomics services the needs of pathologists, oncologists, urologists and other clinicians, and hospitals throughout the United States. For additional information about NeoGenomics, visit

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements.  These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements.  Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs